Key Points
- COO Joseph Gilliam sold 4,502 shares on January 21 at an average price of $124.65 for proceeds of $561,174, reducing his stake by 4.65% to 92,366 shares valued at about $11.51M.
- Shares of GKOS were down ~4.7% (opened $119.96); the company has a market cap of $6.89B, a negative P/E of -77.89, and a 12‑month range of $73.16–$161.78.
- Glaukos beat the last quarter's EPS and revenue estimates (EPS ($0.16) vs. ($0.27) est., revenue $133.5M, +38.1% y/y) but remains unprofitable, while analysts hold a consensus Moderate Buy with a $131.38 target.
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 4,502 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $124.65, for a total transaction of $561,174.30. Following the transaction, the chief operating officer directly owned 92,366 shares of the company's stock, valued at $11,513,421.90. The trade was a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Glaukos Trading Down 4.7%
Shares of GKOS stock opened at $119.96 on Friday. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $161.78. The stock has a market capitalization of $6.89 billion, a P/E ratio of -77.89 and a beta of 0.67. The firm's 50 day moving average is $110.53 and its 200 day moving average is $96.27.
Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The company's quarterly revenue was up 38.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.28) EPS. Research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages have issued reports on GKOS. Stephens raised their target price on Glaukos from $115.00 to $145.00 and gave the stock an "overweight" rating in a research report on Friday, January 2nd. UBS Group upped their price target on shares of Glaukos from $140.00 to $145.00 and gave the company a "buy" rating in a research report on Tuesday, December 23rd. BTIG Research reissued a "buy" rating and issued a $116.00 price objective on shares of Glaukos in a report on Friday, January 2nd. Needham & Company LLC restated a "buy" rating and set a $125.00 target price on shares of Glaukos in a research report on Wednesday, January 14th. Finally, Wells Fargo & Company upped their target price on shares of Glaukos from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $131.38.
Get Our Latest Analysis on GKOS
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC increased its holdings in Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier's stock worth $766,000 after acquiring an additional 198 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Glaukos by 1,405.9% during the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier's stock valued at $252,000 after purchasing an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier's stock worth $22,636,000 after purchasing an additional 67,668 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Glaukos in the second quarter worth approximately $1,245,000. Finally, GAMMA Investing LLC increased its stake in shares of Glaukos by 56.0% in the second quarter. GAMMA Investing LLC now owns 2,109 shares of the medical instruments supplier's stock worth $218,000 after purchasing an additional 757 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
